Save time and jump to the most important pieces.
SC 13G - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Subject)
SC 13G/A - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Subject)
SC 13G - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Subject)
S-1/A - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)
PRE 14A - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)
8-K - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)
LB-100 Generates Neo-Antigens in Cancer Cells that are Presented to the Immune Systemby Disrupting the Process of RNA Splicing
Patent Covers Combining LIXTE's LB-100 with Various Innovative Cancer Immunotherapies PASADENA, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT) ("LIXTE" or the "Company") today announced it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent application number 16/467,721, titled, "Oxabicycloheptanes for Modulation of Immune Response," for combining the Company's LB-100 compound with various innovative cancer immunotherapies. "The patent award further bolsters LIXTE's existing intellectual property portfolio and underscores the Company's commitment to pioneering research and delivering in
PASADENA, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT) ("LIXTE" or the "Company"), today announced the dosing of the first patient in a new clinical trial in collaboration with the Netherlands Cancer Institute (NKI) and supported by F. Hoffmann-La Roche Ltd. ("Roche") for treatment of unresponsive (MSI Low) metastatic colorectal cancer. As part of the clinical trial (NCT06012734, clinicaltrials.gov), LIXTE is providing its lead compound, LB-100, and Roche is providing atezolizumab (Tecentriq ®, a PDL1 inhibitor) through the imCORE Network, a global academic-industry partnership that aims to accelerate cancer immunotherapy research through inst
-Collaboration with NKI and Funding Support for New Colorectal Cancer Clinical Trial by Major Pharma Company- -Distinguished Oncologist Jan Schellens Joins LIXTE as Chief Medical Officer- -Preclinical Data Published in Journal EMBO Reports Shows LB-100 as Potentially Enhancing the Benefit of Immunotherapy- -LIXTE to Present at Two Upcoming Investor Conferences- PASADENA, CA, Aug. 19, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today provided an update on the Company's recent activities. "We are
4/A - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)
4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)
4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)
PASADENA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today announced the appointment of Jan Schellens, M.D., Ph.D., as Chief Medical Officer (CMO). Dr. Schellens brings to LIXTE more than 25 years of clinical experience as a medical oncologist, pharmacologist and clinical pharmacologist, including more than two decades developing and bringing new drugs to market. He assumes the CMO role at LIXTE effective August 1, 2024, succeeding James S. Miser, M.D., who is leaving the Company after serv
Biotechnology Veteran Bas van der Baan Brings Precision Oncology Expertise; Founder John S. Kovach Named Executive Chairman PASADENA, CA, Sept. 26, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage biotechnology company developing a novel class of cancer therapy called PP2A inhibitors, announced that Bas van der Baan has been named as President and Chief Executive Officer of the Company, and as Vice Chairman of the Board of Directors, effective as of September 26, 2023. He has been a member of LIXTE'S Board of Directors since June 2022. Mr. van der Baan succeeds John S. Kovach, M.D., 87, who founded the Company in 2005 a
PASADENA, CA, June 21, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT), a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, announced the appointment of Bas van der Baan to its Board of Directors. He will serve as an independent director. Dr. John S. Kovach, Founder and Chief Executive Officer of Lixte, commented, "We are very pleased to welcome Mr. van der Baan to our Board of Directors. Mr. van der Baan has over 20 years of experience in the biotechnology industry with a key focus on oncology and diagnostics. He has extensive knowhow in the journey from clinical development to reimbursement and commercialization
4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)
4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)
4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)